Sign In
Buy AMPH
$19.94
-0.440 (-2.16%)
At Close: Jul 31, 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2022 Earnings Call Transcript
09:40pm, Monday, 07'th Nov 2022
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Ch
Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates
06:56pm, Monday, 07'th Nov 2022
Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
06:00am, Friday, 28'th Oct 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
11:17am, Monday, 10'th Oct 2022
Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.
Amphastar: A Pharmaceutical Growth Stock
09:53am, Thursday, 06'th Oct 2022
Amphastar's profitability and cash flow have been increasing consistently, and with management's efforts, profitability will increase significantly. Having a solid financial position and consistent gr
7 Safe Stocks to Rely on When the Market Swerves
01:10pm, Monday, 19'th Sep 2022
Back in August, I made the argument why now's the right time to buy safe stocks. Just over a month later, this continues to be the case.
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
06:00am, Friday, 02'nd Sep 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sale
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q2 2022 Results - Earnings Call Transcript
10:33pm, Monday, 08'th Aug 2022
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2022 Results Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Pete
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
08:20pm, Monday, 08'th Aug 2022
Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
04:34pm, Monday, 08'th Aug 2022
Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.
Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
08:00am, Monday, 08'th Aug 2022
Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopre
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
06:05am, Monday, 01'st Aug 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, a
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
01:33pm, Tuesday, 26'th Jul 2022
Amphastar Pharmaceutcls is near a buy zone with earnings due on or around Aug. 9. The post Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings appeared first on Investor's Busine
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
06:05am, Monday, 06'th Jun 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communicat
Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
02:22am, Friday, 13'th May 2022
Amphastar Pharmaceuticals has several key growth drivers: a strong pipeline of products currently awaiting approval, exciting products with growing sales, and growing marketing and distribution channe
